Try GOLD - Free
Greater rivalry and social trust can make Indian capital deliver
Mint Ahmedabad
|September 08, 2025
Indian firms have been underinvesting in innovation and R&D because of policy and social settings
A few days ago, Pratap Bhanu Mehta offered a searing indictment of Indian capitalism in the Indian Express. At a time when tectonic shifts in world politics require Indian capital to step up, he finds that it "shows little appetite for risk, no courage, little ambition for leadership, and little confidence in its own ability to build." He echoes what Naushad Forbes has argued for a long time: that India's top companies underinvest in R&D. At a mere 0.3% of GDP, private spending on R&D is a fifth of the world average. India's ten most profitable firms invest a mere 2% of their profit in research, compared to 29-55% invested by their counterparts in the US, China, Japan and Germany. Alphabet, BMW and Huawei individually invest more in R&D than India's entire private sector does.
Two questions follow: Why is this the case and what can be done about it? Of the many causes, I want to focus on two that I think are most important.
The easier one first: Indian firms are sheltered from competition and have few incentives to innovate. Why invest in R&D when you can sell the same stuff to millions of new customers emerging across the vast country every year? Why venture into something risky—be it R&D or a foreign market—when there are returns to be had by serving the growing domestic market? Substantial parts of the domestic economy remain walled off with FDI restrictions and import tariffs.
This story is from the September 08, 2025 edition of Mint Ahmedabad.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Mint Ahmedabad
Mint Ahmedabad
Pet care startups eye users to compete with FMCG giants
Direct-to-consumer (D2C) pet care brands are leaning on subscription models to lock in customers, betting that repeat purchases can help them counter the scale and distribution advantage of India's largest packaged consumer goods players as the niche segment heats up.
2 mins
January 23, 2026
Mint Ahmedabad
Zydus launches cancer biosimilar
Zydus Lifesciences has launched its biosimilar of anticancer drug nivolumab in India after receiving clearance from the Delhi High Court last week, pricing it at a fraction of the patented version.
1 min
January 23, 2026
Mint Ahmedabad
Retail boosts IPO odds via parent shares
A smart move? Investors are reviving an old strategy by buying parent shares ahead of subsidiary IPOs.
3 mins
January 23, 2026
Mint Ahmedabad
WHY INDIA NEEDS TO RETHINK ITS WAR CHEST
FDI drain is emerging as a silent threat to India's foreign exchange reserves. How can the leak be plugged?
6 mins
January 23, 2026
Mint Ahmedabad
India needs long-term solutions to address its inequality problem
Cash transfers are expedient but we must intervene strongly in the labour market to fix distortions
3 mins
January 23, 2026
Mint Ahmedabad
IndiGo cuts growth outlook as Q3 profit sinks to 4-yr low
Net profit slipped to 549 crore in Q3, hit by a one-time exceptional cost of 1,546.5 crore
3 mins
January 23, 2026
Mint Ahmedabad
Banks renew push to unsecured loans
India's banks are cautiously reopening the tap on unsecured lending, as policy rate cuts drive margin pressure and risks stay largely under control.
1 min
January 23, 2026
Mint Ahmedabad
Blinkit’s Q3 profit a shift or blip?
Eternal Ltd’s Q3FY26 results were encouraging on many counts.
2 mins
January 23, 2026
Mint Ahmedabad
An India-France tale on cloth
A recent Paris show celebrated 400 years of textile history between the two nations, showcasing shared crafts
4 mins
January 23, 2026
Mint Ahmedabad
Small finance banks hunt for peer talent to grow
SFBs are eyeing senior executives at larger banks in universal banking bid
2 mins
January 23, 2026
Listen
Translate
Change font size

